<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font20 { font-size : 20; } .font26 { font-size : 26; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font26">and </span>
   <span class="font20">EBV </span>
   <span class="font17">with </span>
   <span class="font16">{background </span>
   <span class="font15">for </span>
   <span class="font15">virus </span>
   <span class="font15">antiviral </span>
   <span class="font15">that </span>
   <span class="font14">margin </span>
   <span class="font14">[]. </span>
   <span class="font14">viral </span>
   <span class="font14">{border-style </span>
   <span class="font14">px;} </span>
   <span class="font13">#ffffff;} </span>
   <span class="font13">has </span>
   <span class="font13">Epstein-Barr </span>
   <span class="font13">The </span>
   <span class="font13">infection </span>
   <span class="font12">not </span>
   <span class="font12">was </span>
   <span class="font12">but </span>
   <span class="font12">DNA </span>
   <span class="font12">been </span>
   <span class="font12">prophylaxis </span>
   <span class="font12">treatment </span>
   <span class="font12">MBV </span>
   <span class="font12">against </span>
   <span class="font12">its </span>
   <span class="font12">replication </span>
   <span class="font12">were </span>
   <span class="font12">are </span>
   <span class="font12">have </span>
   <span class="font11">activity </span>
   <span class="font11">drugs </span>
   <span class="font11">early </span>
   <span class="font11">px; </span>
   <span class="font11">which </span>
   <span class="font11">{font-family </span>
   <span class="font11">However, </span>
   <span class="font11">PTLD </span>
   <span class="font11">active </span>
   <span class="font11">font-size </span>
   <span class="font11">infectious </span>
   <span class="font11">lymphoproliferative </span>
   <span class="font11">recipients </span>
   <span class="font11">through </span>
   <span class="font11">Agents </span>
   <span class="font11">acute </span>
   <span class="font11">clinical </span>
   <span class="font11">double; </span>
   <span class="font11">effect </span>
   <span class="font11">effects </span>
   <span class="font11">human </span>
   <span class="font11">incidence </span>
   <span class="font11">inhibition </span>
   <span class="font11">late </span>
   <span class="font11">may </span>
   <span class="font11">oral </span>
   <span class="font11">used </span>
   <span class="font11">Epsteinâ€“Barr </span>
   <span class="font11">This </span>
   <span class="font11">[,]. </span>
   <span class="font11">acyclovir </span>
   <span class="font11">also </span>
   <span class="font11">associated </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">can </span>
   <span class="font11">cellular </span>
   <span class="font11">during </span>
   <span class="font11">first </span>
   <span class="font11">inhibitors </span>
   <span class="font11">inhibits </span>
   <span class="font11">latent </span>
   <span class="font11">load </span>
   <span class="font11">nucleoside </span>
   <span class="font11">primary </span>
   <span class="font11">received </span>
   <span class="font11">solid; </span>
   <span class="font11">than </span>
   <span class="font11">there </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font10">ACV </span>
   <span class="font10">Acyclovir </span>
   <span class="font10">EBV-positive </span>
   <span class="font10">GCV </span>
   <span class="font10">HCMV </span>
   <span class="font10">Maribavir </span>
   <span class="font10">VALM </span>
   <span class="font10">approved </span>
   <span class="font10">bold </span>
   <span class="font10">carcinoma </span>
   <span class="font10">cases </span>
   <span class="font10">cells </span>
   <span class="font10">courier; </span>
   <span class="font10">cytomegalovirus </span>
   <span class="font10">dependent </span>
   <span class="font10">disease </span>
   <span class="font10">effective </span>
   <span class="font10">em; </span>
   <span class="font10">from </span>
   <span class="font10">ganciclovir </span>
   <span class="font10">group </span>
   <span class="font10">infected </span>
   <span class="font10">mononucleosis </span>
   <span class="font10">mutations </span>
   <span class="font10">nasopharyngeal </span>
   <span class="font10">onset </span>
   <span class="font10">other </span>
   <span class="font10">placebo </span>
   <span class="font10">pt;} </span>
   <span class="font10">results </span>
   <span class="font10">significantly </span>
   <span class="font10">some </span>
   <span class="font10">their </span>
   <span class="font10">therapy </span>
   <span class="font10">versus </span>
   <span class="font10">who </span>
  </p>
 </body>
</html>
